Boehringer Ingelheim International Gmbh

Boehringer Ingelheim Pharmaceuticals, Inc.

Other

Karl-Heinz Heider

Elinborg Ostermann

Eric Borges

Renate Konopitzky

Paul Adam

Erik Patzelt

Marlies Sproll

Hartmut Beug

John James Miglietta

Augustinus Antonius Maria Silvester Van Dongen

Guenther Adolf

Birgit Jung

Anke Baum

Klaus-Peter Kuenkele

Pankaj Gupta

Peter Seither

Priyanka Gupta

Gunther R Adolf

Andreas Zophel

Stephen R Comeau

Kurt Zatloukal

Philip Nicholas Gorman

Horst Johann Ahorn

Andreas Wernitznig

Sandeep Kumar

Norbert Kraut

Abdulsalam Shaaban

Andreas Weith

Christine Beham-Schmid

Milena Kalat

Srinath Kasturirangan

David Weismann

Thomas Waerner

Taneisha Ann-Tanara Mack

Martin Jechlinger

Ido M Tamir

David S Young

Charlotte Astrid Russell

Stefan Gruenert

Günther Adolf

Martin Oft

Ernst Reichmann

The present invention relates to novel tri-specific binding molecules. The invention also relates to nucleic acids encoding such binding molecules; to methods for preparing such binding molecules; to host cells expressing or capable of expressing such binding molecules; to compositions comprising such binding molecules; and to uses of such binding molecules or such compositions, in particular for therapeutic purposes in the field of cancer diseases.

Tri-specific binding molecules

The present invention relates to immunotherapies that are based on myeloid cell depletion. In particular, the present invention relates to CD33 binding agents for use in such therapies, e.g. in the treatment of myeloid cell malignancies and myelodysplastic syndrome (MDS).

CD33 binding agents

Chimeric and humanized anti-CD37 antibodies and pharmaceutical compositions containing them are useful for the treatment of B cell malignancies and autoimmune and inflammatory diseases that involve B cells in their pathology.

Anti CD37 antibodies

The present invention relates to immunotherapies that are based on depletion of CD37-positive cells such as B-cells. The present invention provides methods for reduction of CD37-positive cells such as B-cells in an individual/patient using a combination of CD37 antibody/antibodies and ICE. The combination of CD37 antibodies and ICE is shown to have improved anti-tumor efficacy compared to single agent treatment. The application further provides materials and methods for treatment of diseases involving aberrant B-cell activity.

Combination of CD37 antibodies with ICE

Anti-FAP-antibodies and immunoconjugates, pharmaceutical compositions containing such conjugates, and their use in cancer therapy.

Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them

The functional characterization of ILEI to be a novel cytokine involved in epithelial/mesenchymal transition and the identification of biologically active ILEI provides the basis for generating ILEI inhibitors, in particular anti-ILEI antibodies, that are useful in the therapy of cancer, fibrosis and COPD.

Antibodies to interleukin-like epithelial-mesenchymal transition inducer (ILEI)

The present invention belongs to the field of oncology. The invention relates to antibodies with specified sequence which are specific for an epitope which is coded by the variant exon v6 of the CD44 gene and to derivatives of said antibody. The invention also provides nucleic acid molecules encoding said antibody proteins. The invention furthermore pertains to methods for producing said antibody proteins. The invention also provides pharmaceutical compositions comprising said antibody proteins. The invention furthermore is concerned with the use in the manufacture of a medicament for the treatment of cancer.

Antibodies specific for CD44v6

The invention relates to novel conjugates of CD44 antibodies with cytotoxic compounds, pharmaceutical compositions comprising such compounds, and their use in tumor therapy.

Cytotoxic CD44 antibody immunoconjugates

Pharmaceutical compositions containing as active compound a substance which inhibits the activity of TGF&bgr; on tumour cells of epithelial origin, for the treatment of epithelial, invasive tumour diseases which are characterized by a reversible transition of the cells from an epithelial, non-invasive state into a fibroblastoid, invasive state. The pharmaceutical composition contains a TGF&bgr; inhibitor, preferably combined with an Ras inhibitor. Process for screening substances for the treatment of epithelial, invasive tumour diseases.

Methods of screening for pharmacologically active compounds for the treatment of tumour diseases

The invention relates to a method for diagnosing and treating Hodgkin's lymphomas (lymphogranulomatosis) which is based on the expression of the variant exon v10 of the CD44 gene as a molecular marker or target. There is a significant correlation between v10 expression and the stage and prognosis of the disease. In a preferred embodiment, v10-specific antibody molecules are used to measure the expression of the exon in samples. In another preferred embodiment, radiolabelled v10-specific antibodies are used to treat Hodgkin's lymphomas.

Method for diagnosis and therapy of Hodgkin's lymphomas

Growing community of inventors

Stockerau, Austria

Karl-Heinz Heider